Byondis 1.png
Byondis_Primary_Logo.png

New corporate brand

Byondis biopharmaceuticals

Byondis, a new globally active pharmaceutical company focuses on intractable cancers and autoimmune diseases.

Based on proprietary technology, Byondis will create new precision drugs with a broad development pipeline, including anti-HER2 ADC [vic-] trastuzumab duocarmazine (SYD985) for breast cancer.

Byondis is a spin-off from Synthon Pharmaceuticals, a multinational that focuses mainly on high-quality generic and hybrid medicines.

Globrands' Pharmanaming and design agency VBAT developed the brand name and verbal and visual identity by interweaving their processes. Globrands responsible for positioning and brand story, brand essence, brand name and tagline, while VBAT was responsible for the logo and visual identity.

Contact us and learn more about the Byondis branding case

Make hope real

The founders, especially Jacques Lemmens, turned out to be remarkably good storytellers, revealing the rich corporate culture that came from parent brand Synthon. Their inspirational stories demonstrated their dedication to challenge cancer and autoimmune diseases. A brand and personality was revealing itself: a passionate and daring explorer, unfathomable knowledge of laboratories with high grade quality and safety regulations; offering desperate patients a possible solution. Globrands had the task of formulating the brand essence, which was expressed in the promise Make hope real.

EVvPYx2XsAAZ1yt.jpg

Byondis has a broad development pipeline, including advanced clinical programs, such as anti-Her2 ADC [vic-]trastuzumab duocarmazine (SYD985) for breast cancer. In the second half of 2020, Byondis is expecting results from its pivotal Tulip Phase III trial comparing SYD985 to the physician's choice treatment in patients with Her2-positive unresectable locally advanced or metastatic breast cancer. Submission of a Biological License Application is scheduled before the end of 2020.

Byondis 3.jpeg

Byondis anticipates entering the clinic with four additional programmes in the course of 2020/2021. After progressing to clinical proof of concept, Byondis intends to enter into partnerships for late-stage development and commercialisation.

Synthon Biopharmaceuticals was established in 2007 as part of Synthon, and became a separate biopharmaceutical subsidiary in 2012, quickly building a promising pipeline of innovative R&D programmes. In November last year, following the acquisition of Synthon International Holding by BC Partners, the founder, Dr. Jacques Lemmens, decided to continue as an independent biopharmaceutical company, with its own management team and state-of-the-art facilities. This company now re-launches as Byondis.

Beyond this

EVuipwgXQAAbnh2.jpg

“As Byondis, we can now showcase our strong business and scientific proposition”, added Dr. Marco Timmers, CEO. “We have generated a portfolio of preclinical and clinical programs with the potential to deliver completely novel treatments for cancer and auto-immune diseases. We have unique technologies with differentiating potential, state-of-the-art facilities including our own GMP manufacturing, and broad licensing expertise that makes us an attractive partner for out-licensing. This is a really exciting time for Byondis and our team.”

Byondis operates from its headquarters in Nijmegen in the Netherlands, with over 350 highly qualified employees working in state-of-the-art research and development and GMP manufacturing facilities. The Company has strong links to academic institutions, global medical communities and the international pharma industry.

“Our re-launch as Byondis is an exciting moment for the Company” said Dr. Jacques Lemmens. “Building on our heritage, while preserving our company culture, we are further progressing in innovation, quality and scientific excellence.”

“Now is the time to step up as an independent biopharmaceutical company, with our exceptional people, unique technologies and a well-established development pipeline, including our lead ADC, [vic-]trastuzumab duocarmazine. I am very proud of how the Company has grown and evolved. The new name, Byondis, represents the next chapter and embodies our entrepreneurial spirit and ambition to create innovative precision medicines to outsmart cancers and auto-immune diseases.”

The Byondis management team has a wealth of scientific, clinical and operational experience, and is well networked within the pharmaceutical industry. Dr. Marco Timmers, CEO, and others in the senior team have collaborated for many years as part of Synthon. During this time, they have created a company driven by science and innovation, with unique technologies and significant validation deals. These include the out-licensing of a biosimilar version of the monoclonal antibody trastuzumab (marketed as Kanjinti) in a global partnership agreement with Amgen in 2012.

New corporate brand Genuone sciences

Genuone is a leading pharmaceutical CDMO (Contract Development Manufacturing Organization) in South Korea capable of providing a wide coverage of drug dosage forms including oral solid, capsules, liquids, injections, and ointments

The name GENUONE was created to evoke the ideas of “GENUINE” and “ONE.” GEN, short for “genuine,” to convey the company's commitment to sincerity and loyalty toward customers. ONE signifies the determination to be The Best Team. Those values are fully instilled in the Genuone Sciences name. Recently established after the acquisition of well-known pharma businesses, Genuone Sciences is a specialized CMO pharmaceutical company that harnesses rich experience and advanced technology in drug development, clinical development capabilities and the most high-end production facilities in the nation. Genuone works to be trusted as a true partner for clients.

Offering an extensive portfolio of pharmaceutical products essential to the future health and happiness of humanity, Genuone Sciences is launching a new era in the pharmaceutical and healthcare industry.

Contact us and learn more about the Genuone 

branding case

Your pharmacy in good hands: the Indivion robot dispenser 

The INDIVION is the most cost-effective solution available on the market due to the reduction in manual labour and a minimal number of errors that equates to almost zero. This technology, together with the use of validated and certified materials, reduces the business risks for medicine dispensers but, more importantly, reduces health risks to patients. And, ultimately, that’s what it’s all about.

The fully-automated INDIVION medicine dosage system comprises an industrial robot that puts canisters, each filled with a specific medication, onto the correct docking stations so that the medications can be dispensed.

The INDIVION canisters each have a unique RFID tag from which the correct information can be read by a reader linked to the PHARYS database so that the reader can determine precisely which medications are in the machine, and how to control this specific canister for the correct dispensation of medicines. Single dose, multi dose, rush orders, expiry date-related changes, production related to method of treatment; all this is possible using the PHARYS software that helps safeguard the entire process-management chain in the central filling pharmacy together with the control of the INDIVION. The INDIVION has unrivalled capacity and produces up to 10,000 individual units per hour, while providing an absolute minimum risk of cross-contamination and incorrect dosage. The dispensation accuracy of 99.97% is also unrivalled in the market.

indivion.2e16d0ba.fill-1440x400.jpg